» Articles » PMID: 29740450

A Novel Three-Dimensional Immune Oncology Model for High-Throughput Testing of Tumoricidal Activity

Overview
Journal Front Immunol
Date 2018 May 10
PMID 29740450
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The latest advancements in oncology research are focused on autologous immune cell therapy. However, the effectiveness of this type of immunotherapy for cancer remediation is not equivalent for all patients or cancer types. This suggests the need for better preclinical screening models that more closely recapitulate tumor biology. The established method for investigating tumoricidal activity of immunotherapies has been study of two-dimensional (2D) monolayer cultures of immortalized cancer cell lines or primary tumor cells in standard tissue culture vessels. Indeed, a proven means to examine immune cell migration and invasion are 2D chemotaxis assays in permeabilized supports or Boyden chambers. Nevertheless, the more -like three-dimensional (3D) multicellular tumor spheroids are quickly becoming the favored model to examine immune cell invasion and tumor cell cytotoxicity. Accordingly, we have developed a 3D immune oncology model by combining 96-well permeable support systems and 96-well low-attachment microplates. The use of the permeable support system enables assessment of immune cell migration, which was tested in this study as chemotactic response of natural killer NK-92MI cells to human stromal-cell derived factor-1 (SDF-1α). Immune invasion was assessed by measuring NK-92MI infiltration into lung carcinoma A549 cell spheroids that were formed in low-attachment microplates. The novel pairing of the permeable support system with low-attachment microplates permitted simultaneous investigation of immune cell homing, immune invasion of tumor spheroids, and spheroid cytotoxicity. In effect, the system represents a more comprehensive and -like immune oncology model that can be utilized for high-throughput study of tumoricidal activity.

Citing Articles

A thermoplastic chip for 2D and 3D correlative assays combining screening and high-resolution imaging of immune cell responses.

van Ooijen H, Verron Q, Zhang H, Sandoz P, Frisk T, Carannante V Cell Rep Methods. 2025; 5(1):100965.

PMID: 39826552 PMC: 11841093. DOI: 10.1016/j.crmeth.2025.100965.


A Thermo-responsive collapse system for controlling heterogeneous cell localization, ratio and interaction for three-dimensional solid tumor modeling.

Li Y, Orange J bioRxiv. 2025; .

PMID: 39764015 PMC: 11703237. DOI: 10.1101/2024.12.26.630018.


Pentoxifylline and Norcantharidin Modify p62 Expression in 2D and 3D Cultures of B16F1 Cells.

Gonzalez-Quiroz J, Ocampo-Godinez J, Hernandez-Gonzalez V, Lezama R, Reyes-Maldonado E, Vega-Lopez A Int J Mol Sci. 2024; 25(10).

PMID: 38791178 PMC: 11121437. DOI: 10.3390/ijms25105140.


Performance of nanoparticles for biomedical applications: The / discrepancy.

Berger S, Berger M, Bantz C, Maskos M, Wagner E Biophys Rev (Melville). 2024; 3(1):011303.

PMID: 38505225 PMC: 10903387. DOI: 10.1063/5.0073494.


A Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine.

Sekeroglu Z, Sekeroglu V Curr Cancer Drug Targets. 2024; 25(2):118-130.

PMID: 38445692 DOI: 10.2174/0115680096285910240206044830.


References
1.
Hoogstad-van Evert J, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R . Umbilical cord blood CD34 progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rg mice. Oncoimmunology. 2017; 6(8):e1320630. PMC: 5593716. DOI: 10.1080/2162402X.2017.1320630. View

2.
Seruga B, Ocana A, Tannock I . Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2010; 8(1):12-23. DOI: 10.1038/nrclinonc.2010.136. View

3.
Kola I, Landis J . Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004; 3(8):711-5. DOI: 10.1038/nrd1470. View

4.
Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D . Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. J Cell Sci. 2016; 130(1):203-218. DOI: 10.1242/jcs.188102. View

5.
Berahovich R, Lai N, Wei Z, Lanier L, Schall T . Evidence for NK cell subsets based on chemokine receptor expression. J Immunol. 2006; 177(11):7833-40. DOI: 10.4049/jimmunol.177.11.7833. View